DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC
The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.
Source: onclive.com
Sumanta Kumar Pal News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sumanta Kumar Pal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sumanta Kumar Pal Today - Breaking & Trending Today
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.
Source: onclive.com
Dr Pal on the Rationale for Investigating Zanzalintinib in Relapsed/Refractory ccRCC
Sumanta Kumar Pal, MD, FASCO, chair, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.
Source: onclive.com
Zanzalintinib Is Promising in Clear-Cell Advanced Renal Cell Carcinoma
Patients with advanced clear cell renal cell carcinoma treated with zanzalintinib had experienced promising antitumor activity with manageable toxicity regardless of prior treatment with cabozantinib.
Source: curetoday.com
Zanzalintinib Continues to Elicit Efficacy With Tolerability in Advanced ccRCC
Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.
Source: onclive.com